Trial · NCT01271712
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival | Regorafenib (Stivarga, BAY73-4506) | 147 | 95% Confidence Interval 122 to 173 | Days | |
| Progression-free Survival | Placebo | 28 | 95% Confidence Interval 28 to 32 | Days | |
| Overall Survival | Regorafenib (Stivarga, BAY73-4506) | 82.0 | Percentage of patients with death | ||
| Overall Survival | Placebo | 80.3 | Percentage of patients with death | ||
| Time to Progression (TTP) | Regorafenib (Stivarga, BAY73-4506) | 165 | 95% Confidence Interval 125 to 174 | Days | |
| Time to Progression (TTP) | Placebo | 28 | 95% Confidence Interval 28 to 34 | Days | |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 0 | Percentage of Participants |
| Tumor Response | Placebo | Complete Response (CR) | 0 | 95% Confidence Interval 0 to 0 | Percentage of Participants |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Partial Response (PR) | 4.5 | 95% Confidence Interval 1.7 to 9.6 | Percentage of Participants |
| Tumor Response | Placebo | Partial Response (PR) | 1.5 | 95% Confidence Interval 0 to 8.2 | Percentage of Participants |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Stable Disease (SD) | 71.4 | 95% Confidence Interval 63.0 to 78.9 | Percentage of Participants |
| Tumor Response | Placebo | Stable Disease (SD) | 33.3 | 95% Confidence Interval 22.2 to 46.0 | Percentage of Participants |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Progressive Disease (PD) | 21.1 | 95% Confidence Interval 14.5 to 29.0 | Percentage of Participants |
| Tumor Response | Placebo | Progressive Disease (PD) | 63.6 | 95% Confidence Interval 50.9 to 75.1 | Percentage of Participants |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Not Assessable | 3.0 | 95% Confidence Interval 0.8 to 7.5 | Percentage of Participants |
| Tumor Response | Placebo | Not Assessable | 1.5 | 95% Confidence Interval 0 to 8.2 | Percentage of Participants |
| Objective Response Rate | Regorafenib (Stivarga, BAY73-4506) | 4.5 | 95% Confidence Interval 1.7 to 9.6 | Percentage of Participants | |
| Objective Response Rate | Placebo | 1.5 | 95% Confidence Interval 0.0 to 8.2 | Percentage of Participants | |
| Disease Control Rate (DCR) | Regorafenib (Stivarga, BAY73-4506) | 52.6 | 95% Confidence Interval 43.8 to 61.3 | Percentage of Participants | |
| Disease Control Rate (DCR) | Placebo | 9.1 | 95% Confidence Interval 3.4 to 18.7 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01271712/results